专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022236364A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT 审中-公开
公开(公告)号：WO2022236364A1
公开(公告)日：2022-11-17
申请号：PCT/AU2022/050437
申请日：2022-05-10
申请人： TOPELIA AUST LIMITED (ACN 652 771 670)
发明人： BORODY, Thomas Julius , DOLAI, Sibasish
IPC分类号： A61K31/00 , A61K39/12 , A61K39/02 , A61K39/002 , G01N33/569 , A61K31/53 , A61P31/00 , A61K35/76 , G01N2469/20 , G01N33/54366
摘要： In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection, or boosting or enhancing natural immunity acquired by an infected individual, by administration of: an inactivated infectious causative agent of the infection, or an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of "vaccine breakthrough infections" after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious agent, and thus also prevents ongoing mutations of the viral infectious agent because using the combination antiviral co-therapy where there is no replication of infectious agent and so there is no possible further mutation of the infectious agent.

IPRDB

热门服务

关于我们

友情链接

联系方式